India hits back at pharma's allegations of deteriorating IPR regime
This article was originally published in SRA
Executive Summary
India is holding its ground against recent allegations by multinational pharma firms Pfizer and Novartis that the intellectual property rights (IPR) regime in the country is deteriorating.